Klotho Neurosciences (NASDAQ:KLTO) Releases Quarterly Earnings Results

Klotho Neurosciences (NASDAQ:KLTO) announced its quarterly earnings results on Thursday. The company reported ($0.05) earnings per share (EPS) for the quarter, Zacks reports.

Klotho Neurosciences Trading Down 2.0%

Shares of KLTO traded down $0.01 during trading hours on Friday, reaching $0.47. 309,401 shares of the company’s stock traded hands, compared to its average volume of 714,815. Klotho Neurosciences has a 12 month low of $0.11 and a 12 month high of $3.91. The stock has a market cap of $32.75 million, a PE ratio of -1.46 and a beta of 10.03. The firm’s 50 day simple moving average is $0.54 and its 200-day simple moving average is $0.72.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Klotho Neurosciences in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Klotho Neurosciences currently has an average rating of “Sell”.

Hedge Funds Weigh In On Klotho Neurosciences

An institutional investor recently bought a new position in Klotho Neurosciences stock. Jane Street Group LLC acquired a new stake in shares of Klotho Neurosciences, Inc. (NASDAQ:KLTO) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 23,364 shares of the company’s stock, valued at approximately $26,000. Jane Street Group LLC owned approximately 0.05% of Klotho Neurosciences as of its most recent filing with the SEC. 20.07% of the stock is owned by institutional investors.

Klotho Neurosciences Company Profile

Klotho Neurosciences, Inc, a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors.